TipRanks
Perspective Therapeutics (CATX)
:CATX
US Market
CATX
Perspective Therapeutics
RESEARCH TOOLSreports
Want to see CATX full AI Analyst Report?

Perspective Therapeutics (CATX) Stock Forecast & Price Target

1,689 Followers
See the Price Targets and Ratings of:

CATX Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Perspective
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CATX Stock 12 Month Forecast

Average Price Target

$12.18
▲(270.27% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Perspective Therapeutics in the last 3 months. The average price target is $12.18 with a high forecast of $18.00 and a low forecast of $5.00. The average price target represents a 270.27% change from the last price of $3.29.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","10":"$10","19":"$19","5.5":"$5.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.181818181818182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.5,10,14.5,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.72,3.8953846153846152,5.070769230769231,6.246153846153845,7.421538461538461,8.596923076923076,9.772307692307692,10.947692307692307,12.123076923076923,13.298461538461538,14.473846153846154,15.649230769230769,16.82461538461538,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.72,3.4478321678321677,4.175664335664336,4.903496503496504,5.631328671328671,6.35916083916084,7.086993006993007,7.814825174825174,8.542657342657343,9.27048951048951,9.998321678321679,10.726153846153846,11.453986013986013,{"y":12.181818181818182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.72,2.8953846153846157,3.0707692307692307,3.246153846153846,3.4215384615384616,3.596923076923077,3.7723076923076926,3.9476923076923076,4.123076923076923,4.298461538461538,4.473846153846154,4.649230769230769,4.8246153846153845,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.43,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$18.00Average Price Target$12.18Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CATX
Alec Stranahan
Bank of America Securities
Bank of America Securities
$5
Hold
51.98%
Upside
Reiterated
10/19/26
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities
RBC Capital Analyst forecast on CATX
Leonid Timashev
RBC Capital
RBC Capital
$14
Buy
325.53%
Upside
Reiterated
10/16/26
Analysts Conflicted on These Healthcare Names: Perspective Therapeutics (NYSE MKT: CATX), Bristol-Myers Squibb (NYSE: BMY) and Incyte (NASDAQ: INCY)
Wedbush Analyst forecast on CATX
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$11
Buy
234.35%
Upside
Reiterated
10/13/26
Perspective Therapeutics (CATX) Receives a Buy from Wedbush
Truist Financial Analyst forecast on CATX
Gregory Renza
Truist Financial
Truist Financial
$11
Buy
234.35%
Upside
Reiterated
10/13/26
Analysts Are Bullish on These Healthcare Stocks: Nurix Therapeutics (NRIX), Perspective Therapeutics (CATX)
UBS Analyst forecast on CATX
David Dai
UBS
UBS
$8
Buy
143.16%
Upside
Reiterated
10/02/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX) and Integra Lifesciences (NASDAQ: IART)
William Blair Analyst forecast on CATX
Andy Hsieh
William Blair
William Blair
―
Buy
―
Initiated
09/18/26
Perspective Therapeutics initiated with an Outperform at William BlairPerspective Therapeutics initiated with an Outperform at William Blair
BMO Capital Analyst forecast on CATX
David Lebowitz
BMO Capital
BMO Capital
$11
Buy
234.35%
Upside
Reiterated
09/14/26
Perspective Therapeutics: Merck Collaboration and 2H26 Catalysts Reinforce Buy Rating and Unchanged $11 Price Target
JonesTrading Analyst forecast on CATX
Justin Walsh
JonesTrading
JonesTrading
$18
Buy
447.11%
Upside
Reiterated
08/14/26
Perspective Therapeutics Earns Buy Rating as Justin Walsh Reaffirms $18 Price Target on Strength of Pb-212 Pipeline and Upcoming Phase III Program
LifeSci Capital Analyst forecast on CATX
Oliver McCammon
LifeSci Capital
LifeSci Capital
$15
Buy
355.93%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (NASDAQ: ATOS), Corvus Pharmaceuticals (NASDAQ: CRVS) and Perspective Therapeutics (NYSE MKT: CATX)
Oppenheimer Analyst forecast on CATX
Jeff Jones
Oppenheimer
Oppenheimer
$13
Buy
295.14%
Upside
Reiterated
08/11/26
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer
BTIG Analyst forecast on CATX
Jeet Mukherjee
BTIG
BTIG
$14
Buy
325.53%
Upside
Reiterated
08/11/26
Perspective Therapeutics: Advancing Pipeline, Strong Fundamentals Support Buy Rating and Unchanged $14 Price Target
Piper Sandler Analyst forecast on CATX
Biren Amin
Piper Sandler
Piper Sandler
$16→$14
Buy
325.53%
Upside
Assigned
08/11/26
Piper Sandler Sticks to Their Buy Rating for Perspective Therapeutics (CATX)
H.C. Wainwright Analyst forecast on CATX
Robert Burns
H.C. Wainwright
H.C. Wainwright
$13
Buy
295.14%
Upside
Reiterated
06/01/26
H.C. Wainwright Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
B. Riley Securities Analyst forecast on CATX
Yuan Zhi
B. Riley Securities
B. Riley Securities
$11→$13
Buy
295.14%
Upside
Assigned
03/18/26
Perspective Therapeutics price target raised to $13 from $11 at B. RileyPerspective Therapeutics price target raised to $13 from $11 at B. Riley
Goldman Sachs Analyst forecast on CATX
Rajan Sharma
Goldman Sachs
Goldman Sachs
―
Buy
―
Reiterated
02/17/26
Buy Rating on Perspective Therapeutics (CATX) Driven by Differentiated Radiopharmaceutical Platform and Undervalued Long-Term Upside
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CATX
Alec Stranahan
Bank of America Securities
Bank of America Securities
$5
Hold
51.98%
Upside
Reiterated
10/19/26
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities
RBC Capital Analyst forecast on CATX
Leonid Timashev
RBC Capital
RBC Capital
$14
Buy
325.53%
Upside
Reiterated
10/16/26
Analysts Conflicted on These Healthcare Names: Perspective Therapeutics (NYSE MKT: CATX), Bristol-Myers Squibb (NYSE: BMY) and Incyte (NASDAQ: INCY)
Wedbush Analyst forecast on CATX
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$11
Buy
234.35%
Upside
Reiterated
10/13/26
Perspective Therapeutics (CATX) Receives a Buy from Wedbush
Truist Financial Analyst forecast on CATX
Gregory Renza
Truist Financial
Truist Financial
$11
Buy
234.35%
Upside
Reiterated
10/13/26
Analysts Are Bullish on These Healthcare Stocks: Nurix Therapeutics (NRIX), Perspective Therapeutics (CATX)
UBS Analyst forecast on CATX
David Dai
UBS
UBS
$8
Buy
143.16%
Upside
Reiterated
10/02/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX) and Integra Lifesciences (NASDAQ: IART)
William Blair Analyst forecast on CATX
Andy Hsieh
William Blair
William Blair
―
Buy
―
Initiated
09/18/26
Perspective Therapeutics initiated with an Outperform at William BlairPerspective Therapeutics initiated with an Outperform at William Blair
BMO Capital Analyst forecast on CATX
David Lebowitz
BMO Capital
BMO Capital
$11
Buy
234.35%
Upside
Reiterated
09/14/26
Perspective Therapeutics: Merck Collaboration and 2H26 Catalysts Reinforce Buy Rating and Unchanged $11 Price Target
JonesTrading Analyst forecast on CATX
Justin Walsh
JonesTrading
JonesTrading
$18
Buy
447.11%
Upside
Reiterated
08/14/26
Perspective Therapeutics Earns Buy Rating as Justin Walsh Reaffirms $18 Price Target on Strength of Pb-212 Pipeline and Upcoming Phase III Program
LifeSci Capital Analyst forecast on CATX
Oliver McCammon
LifeSci Capital
LifeSci Capital
$15
Buy
355.93%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (NASDAQ: ATOS), Corvus Pharmaceuticals (NASDAQ: CRVS) and Perspective Therapeutics (NYSE MKT: CATX)
Oppenheimer Analyst forecast on CATX
Jeff Jones
Oppenheimer
Oppenheimer
$13
Buy
295.14%
Upside
Reiterated
08/11/26
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer
BTIG Analyst forecast on CATX
Jeet Mukherjee
BTIG
BTIG
$14
Buy
325.53%
Upside
Reiterated
08/11/26
Perspective Therapeutics: Advancing Pipeline, Strong Fundamentals Support Buy Rating and Unchanged $14 Price Target
Piper Sandler Analyst forecast on CATX
Biren Amin
Piper Sandler
Piper Sandler
$16→$14
Buy
325.53%
Upside
Assigned
08/11/26
Piper Sandler Sticks to Their Buy Rating for Perspective Therapeutics (CATX)
H.C. Wainwright Analyst forecast on CATX
Robert Burns
H.C. Wainwright
H.C. Wainwright
$13
Buy
295.14%
Upside
Reiterated
06/01/26
H.C. Wainwright Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
B. Riley Securities Analyst forecast on CATX
Yuan Zhi
B. Riley Securities
B. Riley Securities
$11→$13
Buy
295.14%
Upside
Assigned
03/18/26
Perspective Therapeutics price target raised to $13 from $11 at B. RileyPerspective Therapeutics price target raised to $13 from $11 at B. Riley
Goldman Sachs Analyst forecast on CATX
Rajan Sharma
Goldman Sachs
Goldman Sachs
―
Buy
―
Reiterated
02/17/26
Buy Rating on Perspective Therapeutics (CATX) Driven by Differentiated Radiopharmaceutical Platform and Undervalued Long-Term Upside
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
KNSAKiniksa Pharmaceuticals
OMCLOmnicell
AXGNAxoGen
ONCBeOne Medicines
AHCOAdaptHealth
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Perspective Therapeutics

3 Months
Yuan ZhiB. Riley Securities
Success Rate
5/11 ratings generated profit
45%
Average Return
+16.14%
Copying Yuan Zhi's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +16.14% per trade.
1 Year
Jeff JonesOppenheimer
Success Rate
7/24 ratings generated profit
29%
Average Return
-0.30%
Copying Jeff Jones's trades and holding each position for 1 Year would result in 29.17% of your transactions generating a profit, with an average return of -0.30% per trade.
2 Years
Justin WalshJonesTrading
Success Rate
1/23 ratings generated profit
4%
Average Return
-41.15%
Copying Justin Walsh's trades and holding each position for 2 Years would result in 4.35% of your transactions generating a profit, with an average return of -41.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CATX Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
22
18
15
14
17
Buy
3
2
0
2
2
Hold
4
3
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
23
16
17
21
In the current month, CATX has received 19 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CATX average Analyst price target in the past 3 months is 12.18.
Each month's total comprises the sum of three months' worth of ratings.

CATX Financial Forecast

CATX Earnings Forecast

Next quarter’s earnings estimate for CATX is -$0.24 with a range of -$0.31 to -$0.20. The previous quarter’s EPS was -$0.22. CATX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year CATX has Performed in-line its overall industry.
Next quarter’s earnings estimate for CATX is -$0.24 with a range of -$0.31 to -$0.20. The previous quarter’s EPS was -$0.22. CATX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year CATX has Performed in-line its overall industry.

CATX Sales Forecast

Next quarter’s sales forecast for CATX is $62.00K with a range of $0.00 to $167.00K. The previous quarter’s sales results were $81.00K. CATX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year CATX has Performed in-line its overall industry.
Next quarter’s sales forecast for CATX is $62.00K with a range of $0.00 to $167.00K. The previous quarter’s sales results were $81.00K. CATX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year CATX has Performed in-line its overall industry.

CATX Stock Forecast FAQ

What is CATX’s average 12-month price target, according to analysts?
Based on analyst ratings, Perspective Therapeutics’s 12-month average price target is 12.18.
    What is CATX’s upside potential, based on the analysts’ average price target?
    Perspective Therapeutics has 270.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CATX a Buy, Sell or Hold?
          Perspective Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Perspective Therapeutics’s price target?
            The average price target for Perspective Therapeutics is 12.18. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $18.00 ,the lowest forecast is $5.00. The average price target represents 270.27% Increase from the current price of $3.29.
              What do analysts say about Perspective Therapeutics?
              Perspective Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of CATX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.